Background: HIV-infected individuals have a 1.5 to 2-fold increased risk for atherosclerotic cardiovascular disease (ASCVD) compared to non-HIV individuals.Aim: Determine the use of statins among adults with and without HIV from 2011 through 2015.Methods: Adults ≥19 years of age with commercial health insurance in the Marketscan database who had HIV infection (n=125,101) and age-sex matched controls without HIV (n=500,404) were included in the current analysis. ASCVD risk was categorized as a history of ASCVD (history of CHD, stroke or peripheral arterial disease); diabetes without a history of ASCVD; and no history of ASCVD or diabetes. Statin use was identified through pharmacy claims.Results: A higher percentage of non-HIV versus HIV infected adults with ASCVD and diabetes were taking statins in each year (Figure). Among adults without ASCVD or diabetes, statins were more commonly used among those with versus without HIV. Among adults with ASCVD and diabetes in 2015, those with versus without HIV were less likely to be taking a statin (multivariable-adjusted prevalence ratio 0.92; 95% CI: 0.88 - 0.97 and 0.89; 95% CI: 0.85 - 0.94, respectively). Among adults without ASCVD or diabetes, those with versus without HIV were less likely to be taking a statin (multivariable-adjusted prevalence ratio 1.07; 95% CI: 1.04 - 1.11) in 2015.Conclusions: Adults with ASCVD or diabetes who have HIV are less likely to be taking statin therapy compared with their counterpart without HIV. The higher use of statins in HIV versus non-HIV individuals without ASVD or diabetes may reflect increased healthcare provider awareness of the high ASCVD risk among HIV-infected adults.